Neurology
Alzheimer's & Dementia
Epilepsy
Headache & Migraine
Multiple Sclerosis
Neurology
Conferences
- Salix's NDA for crofelemer in HIV-associated diarrhea assigned priority review status
- Genentech's BLA for pertuzumab receives priority review status in previously untreated HER2-positive metastatic breast cancer indication
- FDA reviewers questions efficacy of NeurogesX's Qutenza pain patch in proposed new use
- Shire's Vyvanse approved for maintenance treatment in adults with ADHD
- FDA accepts Ziopharm's IND application for oral formulation of Zymafos
- Private FFS MA plans may be linked with higher costs for beneficiaries, GAO report shows
- Pediatric subspecialty telephone consultations may be cost-saving for Medicaid, research reveals
- Use of mental health services greater in health plans with parity in cost sharing, data find
- Public opinions appear split on health care affordability, satisfaction, survey finds
- In Brief: California Supreme Court
AAN 2007 Annual Meeting
April 28 - May 5, 2007 Boston, MA- SleepMed Insomnia Index may help characterize insomnia symptoms in patients with RLS; scores correlate with RLS severity
- Undiagnosed sleep disorders appear common in patients with MS, fatigue, analysis reveals
- Adding eszopiclone to escitalopram improves insomnia symptoms in individuals with insomnia, GAD, study shows
- Sleep dysregulation common in patients with Huntington's disease
- Eszopiclone appears to improve sleep in people with primary insomnia without next-day impairments in cognitive, psychomotor performance, driving abilities
- Impax seeks approval of IPX066 for PD
- FDA approves Mylan's first-to-file generic Keppra XR
- Baxter seeks additional indication for Gammagard liquid
- Genzyme's MS drug candidate fails to show superiority to Pfizer, EMD Serono's Rebif in pivotal study
- FDA approves shared REMS for transmucosal immediate-release fentanyl products
- UCB, Otsuka discontinue immunology collaboration, focus on development of CNS drugs in Japan
- Biogen Idec, Isis collaborate to develop treatment for spinal muscular atrophy
- FDA clears EpiCept's AmiKet for Phase III development in chemotherapy-induced peripheral neuropathy
- UCB's Keppra approved as adjunctive therapy for partial-onset seizures in infants, young children
- BMS expands, extends agreements with Simcere, NeurOp
